The Icam1 Knockout AR42J Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the AR42J rat pancreatic acinar cell line, targeting the Icam1 gene (Intercellular Adhesion Molecule 1). This polyclonal cell population carries heterogeneous disruptions in the Icam1 locus, providing a loss-of-function model for studying ICAM1-dependent processes. The knockout abrogates ICAM1 protein expression and impairs its cell adhesion and signaling functions.
The AR42J cell line originates from an azaserine-induced pancreatic acinar carcinoma in Rattus norvegicus and retains features of exocrine pancreatic acinar cells, including the capacity for enzyme secretion. These cells are widely used as a model for pancreatic acinar cell biology, pancreatitis, and pancreatic cancer, owing to their responsiveness to hormonal and inflammatory stimuli. The AR42J background provides a physiologically relevant context for examining ICAM1 function in pancreatic inflammation and immune cell interactions.
ICAM1 is a transmembrane glycoprotein that mediates cell?Ccell adhesion through interactions with integrins such as LFA-1 (??L??2) and Mac-1 (??M??2), as well as with fibrinogen and hyaluronan. Its expression is transcriptionally upregulated by pro-inflammatory mediators including TNF-alpha, IL-1beta, and interferon-gamma, acting via NF-kB signaling. Upon ligand engagement, ICAM1 activates downstream signaling cascades involving SRC kinases, p130Cas, cortactin, and the MAPK/ERK pathway, ultimately modulating NF-kB activity and promoting leukocyte transendothelial migration. In the AR42J knockout cells, disruption of Icam1 eliminates these adhesive and signaling functions, leading to defective immune cell interaction and transmigration processes.
In the pancreatic acinar context, ICAM1 contributes to the recruitment of leukocytes during pancreatitis and inflammatory responses. Loss of ICAM1 in AR42J cells abolishes cytokine-induced adhesion and impairs the transduction of signals from TNF-alpha and IL-1beta, thereby disrupting downstream inflammatory cascades. This knockout model therefore constitutes a valuable tool for dissecting the role of ICAM1 in pancreatic inflammation, immune cell trafficking, and acinar cell signaling, without confounding effects from full organismal knockouts.
This polyclonal knockout cell population is suitable for a range of experimental applications including adhesion assays to quantify leukocyte?Cacinar cell binding, cytokine stimulation experiments (e.g., with TNF-alpha or IL-1beta) to assess inflammatory signaling, and drug testing for anti-inflammatory agents targeting ICAM1-dependent pathways. Researchers can employ western blotting, flow cytometry, immunofluorescence, and RT-qPCR to validate ICAM1 disruption and monitor downstream signaling events such as MAPK/ERK phosphorylation or NF-kB activation. For further information and technical support, please contact Ascent Research.
